Veracyte | VCYT - 销售和管理费用

金融业

USD

USD 1.41B

现金及等价物

USD 362.58M

USD 39.29M

USD 488.38M

USD 59.94M

USD 39.65M

USD 24.63M

USD 42.31M

824

EPS每股收益

USD 0.52

股本和储备

USD 1.31B

USD 101.97M

债务利息支出

USD 2K

USD 3.48M

USD 0

USD 2.62B

USD 41.15M

USD 116.01M

USD 24.63M

普通股股本

USD 79.05M

45.3

USD 40.63M

USD 139.07M

销售和管理费用

USD 43.31M

USD 20.55M

贸易债权人

USD 4.59M

应收帐款人

USD 44.66M

	销售和管理费用	更改		日
Agenus	USD 10.56M		13.04M	2025-12
Agilent	USD 476M		48M	2025-12
Anika Therapeutics	USD 10.01M		14K	2025-12
Arrowhead Research	USD 46.02M		8.84M	2025-12
Bruker	USD 247.2M		4.7M	2025-12
Heron Therapeutics	USD 23.74M		605K	2025-12
Illumina	USD 272M		11M	2026-03
Intrexon	USD 10.31M		41K	2024-06
Karyopharm Therapeutics	USD 9.56M		17.63M	2025-12
Laboratory Of America	USD 551M		12.4M	2026-03
Ligand Pharmaceuticals	USD 28.45M		8.27M	2025-09
Myriad Genetics	USD 122.3M		6.7M	2025-12
Rigel Pharmaceuticals	USD 27.04M		1M	2024-09
Roche Holding	CHF 7.28B		3.99B	2025-12
Sangamo BioSciences	USD 9.64M		1.83M	2024-06
Siemens	EUR 3.61B		489M	2025-12
Sonic Healthcare	AUD 2.52B		2.46B	2024-12
Thermo Fisher Scientific	USD 1.8B		179M	2026-03
Veracyte	USD 43.31M		8.43M	2025-12
Waters	USD 394M		153.99M	2026-03